A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

Inclusion Criteria01: 1. Voluntary participation and ability to sign informed consent (post-TACE); 2. Age between 18 and 75 years; 3. Diagnosed as HCC based on pathology or clinical criteria, with a BCLC stage of A or B; 4. Patients undergo contrast-enhanced spectral CT 4-8 weeks after treatment and are assessed as complete response on conventional CT images; 5. Patients are scheduled to undergo surgical resection within one month, or DSA hepatic arteriography or contrast-enhanced MRI within one week. If none of these were planned, the patients were scheduled for imaging follow-up (CT or MRI) every 3 months (±15 days) for at least one year. Inclusion Criteria02: 1. Voluntary participation and ability to sign informed consent (post-TACE, cTACE or DEB-TACE); 2. Age between 18 and 75 years; 3. Diagnosed as HCC based on pathology or clinical criteria, with a BCLC stage of A or B; 4. Patients plan to undergo liver tumor resection following TACE downstaging therapy; 5. Contrast-enhanced spectral CT was performed within 7 days before liver resection, after completion of TACE down-staging treatment. Exclusion Criteria: 1. Contraindications to contrast-enhanced CT or contrast-enhanced MRI; 2. Presence of extrahepatic malignancies; 3. History of radiotherapy; 4. Poor image quality or incomplete clinical/imaging data; Withdrawal from the study midway.